INVO Fertility (NASDAQ:IVF) Trading Down 6% – What’s Next?

Shares of INVO Fertility, Inc (NASDAQ:IVF) traded down 6% on Thursday . The stock traded as low as $1.51 and last traded at $1.58. 43,171 shares were traded during mid-day trading, a decline of 10% from the average session volume of 48,143 shares. The stock had previously closed at $1.68.

Analysts Set New Price Targets

Several research analysts have weighed in on the company. Weiss Ratings upgraded INVO Fertility from a “sell (e)” rating to a “sell (e+)” rating in a research note on Wednesday, May 6th. Wall Street Zen upgraded INVO Fertility from a “sell” rating to a “hold” rating in a research note on Saturday, March 7th. Finally, Maxim Group set a $20.00 target price on INVO Fertility in a research note on Tuesday, February 10th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $20.00.

INVO Fertility Trading Up 3.8%

The firm has a 50 day simple moving average of $2.36 and a two-hundred day simple moving average of $6.01. The company has a market capitalization of $2.66 million, a PE ratio of 0.00 and a beta of 2.31.

Institutional Trading of INVO Fertility

An institutional investor recently bought a new position in INVO Fertility stock. Citadel Advisors LLC purchased a new stake in INVO Fertility, Inc (NASDAQ:IVF) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 66,849 shares of the company’s stock, valued at approximately $51,000. Citadel Advisors LLC owned approximately 1.19% of INVO Fertility at the end of the most recent reporting period. 12.02% of the stock is currently owned by institutional investors.

INVO Fertility Company Profile

INVO Fertility (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.

The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation.